Back to Results
First PageMeta Content



Chairman’s Note Idelalisib the is first agent to target the phosphatidylinositol-3-kinase (PI3K) pathway and the second oral agent approved by the FDA, in July 2014, for treatment of relapsed/refractory chronic lymphoc
Add to Reading List

Document Date: 2015-08-06 13:19:29


Open Document

File Size: 149,58 KB

Share Result on Facebook
UPDATE